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Nitric oxide (NO) participates in a diverse array of biological functions in mammalian organ systems. Depending on the biochemical
environment, the production of NO may result in cytoprotection or cytotoxicity. The paradoxical actions of NO arise from the complexities
generated by the redox milieu, NO concentration/bioavailability, and tissue/cell context, which ultimately result in the wide range of regulatory
roles observed. Additionally, in physiological versus pathological states, NO often displays diametrically opposing affects in several organ
systems. Here, we will discuss the roles of NO during reproduction, organ system development, in particular, the cardiovascular system, and its
potential implications in diabetes-induced fetal defects.
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The small polyvalent molecule, nitric oxide (NO), is gener-
ated by three conserved nitric oxide synthases (NOSs) iso-
zymes: endothelial NOS (eNOS; Type III NOS (NOS-3))
located on human chromosome 7q35–7q36; inducible NOS
(iNOS; Type II NOS (NOS-2) macNOS, hepNOS) located on
human chromosome 12q24.2–7q36; and neuronal NOS
(nNOS; Type I NOS (NOS-1) bNOS) located on human chro-
mosome 17cen–17q11.2; and the recently discovered mito-
chondrial NOS (mtNOS) (Lacza et al., 2005; Moncada et al.,
1997; Nicotera et al., 1999). The control of NOS isoform
expression is complex, involving transcriptional and post-tran-
scriptional mechanisms triggered by multiple signaling path-
ways during development, growth, homeostasis, and in a broad
range of pathophysiological conditions (Kleinert et al., 2004; Li
et al., 2002; Wang et al., 1999). In addition to the complex
regulation of NOS expression, NOS isoform subcellular local-
ization, association with receptors, and catalysis are modulated
by a large diverse number of distinct binding proteins, some of
which are capable of binding to e-, i-, and n-NOS (calmodulin),
while others bind to individual isoforms (Dynamin-2 to eNOS,⁎ Corresponding author. Fax: +1 203 785 7303.
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albeit having distinct effects on the particular isoform) (Kone
et al., 2003; Zhang et al., 2003).
NOSs catalyze the oxidation of L-arginine to NO and L-
citrulline, using the cofactors, NADPH, FAD, and tetrahydro-
biopterin (BH4). The constitutively expressed eNOS and nNOS
additionally require Ca2+-calmodulin. Upon generation, NO
freely diffuses through the cell membrane into the extracellular
space reaching tissues up to a distance of 100 μm in a few
seconds at 37°C, limited only by its half life and chemical
reactivity. Subsequently, NO modifies protein thiols (S-nitrosy-
lation or disulfide formation) or cysteine residues (to sulfenic
and sulfinic acid). Additionally, NO can interact with free
radicals to induce a variety of biological responses (Lacza et
al., 2005; Nicotera et al., 1999; Stamler, 1994; Stamler et al.,
1992).
NO is a pleiotropic molecule that acts as a vasoactive agent,
signaling molecule, neurotransmitter, and free radical in mam-
malian systems. NO participates in numerous biological func-
tions including gene expression, cell growth, immune response,
and matrix remodeling in several organ systems including the
central nervous, cardiovascular, and immune systems. NO med-
iates these responses by interacting with several signaling path-
ways. The classic action of NO is activation of guanylate
cyclase that subsequently acts on target proteins. Additionally,
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activated protein kinase (MAPK), janus kinase (JAK), and c-
Jun N-terminal kinase (JNK) pathways. Transcription of sever-
al gene classes, such as cytokines, pro-inflammatory molecules,
matrix proteins, matrix metalloproteinases, and hormones, is
regulated by NO. NO also modulates reactive oxygen depend-
ing on signaling pathways by combining with reactive oxygen
species (ROS) (Brune et al., 2001; Pineda-Molina and Lamas,
2001) which have been demonstrated to play a role in growth
factor signaling including NGF- and VEGF-mediated signaling
(Akassoglou, 2005; Erwin et al., 2005).
NO plays a dual role as a protectant and antagonist in
disease states (Chen et al., 2005; Martins et al., 1998; Moore
and Hui, 2005; Nicotera et al., 1999). The biology of NO is
quite complex but can be understood by examining its bioavail-
ability, chemistry, and the redox microenvironment (Brune et
al., 1999; Naseem, 2005; Nicotera et al., 1999). NO can directly
react with molecules (metalloproteins) or can react with transi-
tion metals, oxygen, or superoxide anion (ROS) producing
potent reactive nitrogen species which then oxidize or nitrosy-
late targets, some of which are antioxidants. NO binds two
reactive oxidants produced by H2O2, metalloxo- and peroxo-
species. Additionally, NO induces cyclooxygenase-2, a mole-
cule found to protect against apoptosis in macrophages and
cardiomyocytes by up-regulation of CuZn-superoxide dismu-
tase, heme oxygenase-1, heat shock protein 70, Mn-superoxide
dismutase, and Bcl-2 (Brune et al., 1999). NO and reactive
nitrogen species are far less genotoxic than ROS. However,
NO rapidly combines with ROS to produce a variety of highly
reactive secondary species which depending on the concentra-
tions of both ROS and NO create unique redox environments
that are detrimental to cell systems in numerous disease states
(Brune et al., 1999; Nicotera et al., 1999).
NOS knockout mouse phenotypes
While pharmacological approaches have provided signifi-
cant insights into the dynamic and complex roles of NO in
cellular, organ, and organismal biology, this approach is limited.
The generation and use of single and multiple NOS isoform
deficient mice have provided an independent approach to eluci-
date the distinct and shared roles of NOS isoforms (Gregg,
2003; Mashimo and Goyal, 1999). Single NOS knockout mice
have aided investigators in resolving the complexities of the NO
signaling systems, as well as the redundancy and compensation
that occur in the absence of individual isoforms (Tranguch and
Huet-Hudson, 2003). For example, retinal vascularization in the
eNOS knockout is normal due to redistribution of nNOS to the
deep capillary plexus leading to normal levels of NO in the
endothelium (Al-Shabrawey et al., 2003). Similarly, compensa-
tion occurs by the generation of splice variants that lead to
persistent low enzyme activity (b5% wildtype NO production),
allowing development to proceed normally. Furthermore, these
splice variants often display tissue specificity leading to unique
affects on organ system development (Forstermann et al., 1998;
Huber et al., 1998; Kolesnikov et al., 1997; Mashimo and
Goyal, 1999; Panda et al.).Interestingly, the generation of NOS isoform double knock-
out mice did not result in decreases in litter sizes (Tranguch and
Huet-Hudson, 2003) but did result in significant decreases in
the generation of double knockout pups (12 compared to the
expected 48 out of 773 pups) (Tranguch and Huet-Hudson,
2003). These data are consistent with the concept that double
NOS knockouts exhibit a developmental abnormality resulting
in perinatal loss, although the stage at which the conceptuses
are lost is currently unknown as are the specific developmental
anomalies.
Recently, a triple NOS knockout mouse was generated
(Morishita et al., 2005). These mice exhibited marked reduc-
tions in survival and fertility rates and higher systolic blood
pressure (similar to that observed in the single and double
knockout mice). Additionally, the surviving mice were noted
to exhibit hypotonic polyuria, polydipisia, and unresponsive-
ness to vasopressin, consistent with a picture of nephrogenic
diabetes insipidus.
The full impact of NOS dysregulation and/or deficiency(ies)
on embryonic development is still largely unknown and war-
rants further investigation. The known specific defects of se-
lected single and double knockouts will be discussed in
subsequent sections.
NO in reproduction/early preimplantation development
NO participates in numerous biological processes associated
with reproduction and embryogenesis (Gouge et al., 1998).
Several studies have demonstrated a role for NO in ovulation,
pregnancy, and preimplantation embryogenesis. Furthermore,
multiple reproductive tissues, including the ovary, fallopian
tubes, and uterus, express NOS isoforms. In the female repro-
ductive tract, NO has been shown to play a role in ovulation
and pregnancy through NOS inhibitor studies that resulted in
inhibition of ovulation and inhibition/termination of pregnancy
(Ekerhovd et al., 1997; Shukovski and Tsafriri, 1995; Telfer et
al., 1995). Additionally, the oocyte and preimplantation embryo
express NOS isoforms, suggesting a role for NO in oocyte
meiotic maturation and early embryo development (Gouge et
al., 1998; Purcell et al., 1999). Concomitantly, eNOS knockout
mice exhibit defects in ovulation and oocyte meiotic maturation
(Jablonka-Shariff and Olson, 1998). However, iNOS-derived
NO has been suggested to play an inhibitory role during fertil-
ization, suggesting isoform-specific reproductive affects (Yang
et al., 2005).
Furthermore, Gouge et al. demonstrated that NO was pro-
duced by preimplantation murine embryos and that embryos (2-
cell to blastocyst stage) cultured with a NOS inhibitor were
developmentally delayed or nonviable. The authors speculated
that NO participates in implantation and demonstrated for the
first time that NO is required for early embryonic development
in mice (Gouge et al., 1998). Subsequent studies, using both
low and high concentrations of a NO donor (10−5 and 10−7 M),
have also elicited inhibition of preimplantation embryonic de-
velopment demonstrating the importance of maintaining the
appropriate NO concentration, with too little or too much
having significant effects on embryonic development (Sengoku
27A.K. Nath, J.A. Madri / Developmental Biology 292 (2006) 25–33et al., 2001). This tight regulation of NO during embryonic
development is reminiscent of observations made in VEGF
expression in hypo- and hyper-morphic transgenic mice,
which also exhibit abnormalities in embryonic development
(Miquerol et al., 1999, 2000).
During the implantation process, NO has been demonstrated
to be required for implantation by intrauterine administration of
a NOS inhibitor. The trophoblast giant cells (TGCs) express
eNOS and iNOS, and the trophoblast of the implanting blasto-
cyst produces NO (Gagioti et al., 2000). NO mediates events
during the invasion process at the fetal–maternal interface
(Nathan and Xie, 1994; Novaro et al., 1997) through matrix
remodeling (Chwalisz et al., 1996), vascular permeability, and
inflammatory responses (Salvemini et al., 1993). Furthermore,
in postimplantation embryos (E7.5), only the TGCs at the
implantation site generate NO (Purcell et al., 1999), thus sup-
porting the role of NO as a required mediator of blastocyst
implantation at the uterine endometrium.
NO in nervous system development
NO has been demonstrated to play a role in the differentia-
tion and development of several organ systems. eNOS/nNOS
double knockout mice display delayed ipsilateral retinocollicu-
lar projection refinement (removal of inappropriately located
axons), suggesting a role for nitric oxide as a repellent molecule
during normal neuronal development (Wu et al., 2000). NO-
dependent synaptic plasticity has also been demonstrated in the
chick ipsilateral retinocollicular projection, chick growth cones
cultures, and frog retinal explant cultures. In addition to a role
in regressive events in the CNS, NO affects neurotransmitter
release and synaptic efficiency (Mize and Lo, 2000; Wu et al.,
2000) as well as being required for postsynaptic differentiation
of the embryonic neuromuscular junction (Bicker, 2005; God-
frey and Schwarte, 2003; Schwarte and Godfrey, 2004). NO has
also been demonstrated to control the balance between cell
proliferation and differentiation, thus controlling body size
(Kuzin et al., 1996). In a later study, NO was found to affect
the Rb signaling pathway, regulating entry into S phase of the
cell cycle in the developing eye (Kuzin et al., 2000).
NO in lung system development
Given its importance in early developmental processes and
the observation that NOS deficient mice exhibited increased
neonatal mortality, potential later developmental NO-mediated
processes including branching morphogenesis were investigat-
ed. Using a rodent day 13 fetal lung explant model, Young et
al. demonstrated an effect of NO on pulmonary branching
morphogenesis using both selected NO donors and NOS inhi-
bitors, eliciting increased branching with exogenous NO
donors and decreased branching with NOS inhibitors (Young
et al., 2002). In a later study, Han et al. demonstrated that eNOS
deficient mice exhibited major defects in lung morphogenesis
including thickening of saccular septae, abnormalities in epi-
thelial differentiation and airway development, reduced surfac-
tant production, a paucity of distal arteriolar branches, capillaryhypoperfusion, and misalignment of pulmonary veins in addi-
tion to congenital cardiac malformations (Han et al., 2004). The
abnormal development of the distal arteriolar network was
found to be similar to what was observed in a transgenic
mouse expressing only VEGF A120 (Galambos et al., 2002),
suggesting that NO may regulate angiogenic gene expression in
the lung, which is known to have important effects on epithelial
as well as endothelial development. The authors found these
abnormalities to be very similar to the characteristics of alve-
olar capillary dysplasia in the human newborn population,
illustrating the importance of NO regulation in human devel-
opment and its effects in the neonatal period (Han et al., 2004).
NO in the cardiovascular system
In 1980's, NO was isolated as a factor that induces vasodi-
lation and lowers blood pressure. Since then, it has been dis-
covered to have numerous roles in endothelial cell and vascular
biology, affecting migration, proliferation, apoptosis and tube
formation, platelet activation and aggregation, platelet–lueko-
cyte interactions, cell adhesion molecule expression, and tissue
factor expression (Naseem, 2005). The generation of eNOS
deficient mice significantly aided our understanding of the
roles this NOS isoform and its product, NO, play in the devel-
opment of the cardiovascular system. Though the eNOS KO
mice are viable, perinatal, newborn, and adult demise is not
infrequent and these mice display fetal growth retardation
(Feng et al., 2002; Lee et al., 2000). eNOS deficient neonates
display bicuspid aortic valves (Lee et al., 2000) and atrial and
ventricular septal defects (Feng et al., 2002). Further investiga-
tions of eNOS wildtype, heterozygous, and null mice revealed
direct relationships between the levels of eNOS and survival,
cardiac fractional shortening, pulmonary congestion and septal
defects, and inverse relationships between levels of eNOS and
caspase-3 activity and myocardial and endocardial cushion
apoptosis (Feng et al., 2002). In addition to these and many
other murine-based studies, the complex roles of NOS and NO
in cardiovascular development have been studied using the
chick embryo. In a recent study, chronic NOS inhibition elicited
impairment of endothelium-dependent relaxation and structural
remodeling of the pulmonary vascular bed as well as biventri-
cular increases in cardiac wall areas (Villamor et al., 2005).
In addition, Feng et al. also observed an inverse relationship
between eNOS levels and myocardial apoptosis/cell death in
eNOS wildtype, heterozygous, and null mice (Feng et al.,
2002). These data are consistent with the concept that eNOS
expression levels (and thus NO production) are an important
modulator of cardiac development, likely affecting the epithelial
to mesenchymal transformation in the endocardial cushion areas,
myocyte survival and myocardial angiogenesis and remodeling,
and dysregulation of this NOS isoform in the heart resulting in
structural congenital abnormalities and myocardial functional
abnormalities (manifested by decreased fractional shortening),
ultimately resulting in heart failure and increased mortality.
These findings, coupled with data illustrating abnormal limb
development in eNOS deficient mice (focal acute hemorrhages
in the distal limbs and shortened peripheral digit bones), are
Fig. 1. The dynamic localization and expression of NOS isoforms during the
development of the vitelline circulation. (A–D) In vitro culture of murine
conceptuses from 7.5 dpc (A, B) to 9.5 dpc (C, D). Illustrated is the develop-
ment of the vitelline vasculature and organogenesis. The yolk sac is observed to
consist of an endodermal layer (En) overlying a layer of mesoderm (Mes), from
which angioblasts will differentiate, which will further differentiate into the
endothelia of the yolk sac vasculature (V). (E–J) Expression pattern of NOS
isoforms during three stages of vascular development. Conceptuses were ex-
cised from timed pregnant matings at 8.0 dpc (A, D), 8.5 dpc (B, E), and 9.5 dpc
(C, F) which correspond to the blood island formation, primary capillary plexus,
and vessel maturation stages, respectively. Immunofluorescence for eNOS (E–
G) and iNOS (H–J) was performed (red = NOS, blue = DAPI). Images of single
blood islands or vessels stained with NOS were captured at 40× magnification
and merged with DAPI images. En = endoderm and Me = mesoderm/endothe-
lium (n ≥ 4) (data derived from Nath et al., 2004). (K and L) Temporal
distribution of endogenous NOS isoforms during vascular development. (K)
Graph of Erk-2 normalized data for NOS protein expression in pooled in vivo
grown 7.5 conceptuses and 8.5 and 9.5 yolk sacs. The dashed line represents
eNOS, while the solid black line represents iNOS (n = 4, P b 0.05, P b 0.01).
The quantified signals represent mean ± SEM. The relative expression levels
were compared to 7.5 dpc levels. (L) Representative Western blot of the
graphed data (data taken from Nath et al., 2004).
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play in humans suffering with Holt–Oram (heart–hand) syn-
drome (Basson et al., 1994; Feng et al., 2002; Hefler et al., 2001).
The role of eNOS and NO in cardiac myocyte development is
complex, with NO playing roles in cardiomyogenesis and in
myocardial angiogenesis (Bloch et al., 1999; Zhao et al., 2002).
Specifically, murine embryonic hearts were found to express
iNOS and eNOS starting at E8.5 (C-looped tubular heart stage).
At later time points, cardiac iNOS expression was diminished,
while only minor reductions in eNOS were noted, suggesting
the participation of specific NOS isoforms in the process of
cardiomyogenesis (Bloch et al., 1999). Interestingly, ectopic
iNOS expression and activity accompany various diseases in
the cardiovascular system. Induction of the high flux iNOS
enzyme is believed to play a role in the pathophysiology of
these diseases, while the low flux eNOS enzyme serves a pro-
tective function (Gewaltig and Kojda, 2002; Shah, 2000). The
importance of NOS activity and NO production during cardio-
myogenesis was confirmed using murine ES-cell-derived cardi-
omyocytes. Treatment of these ES-cell-derived cardiomyocytes
with NOS inhibitors resulted in decreased development of dis-
tinct cross-striation patterns in the cells, consistent with a block
in maturation, and addition of NO donor reversed this effect.
These studies raised the possibility that a potentially direct role
for NO in cardiomyocyte maturation could partially explain the
development of heart failure observed in eNOS deficient mice.
Regarding the diminished myocardial angiogenesis ob-
served in eNOS deficient mice, Zhao et al. (2002) suggested
that the diminished production of NO in eNOS deficient mice
would alter VEGF signaling as well as the persistence of VEGF
expression (as the angiogenic effect of VEGF is thought to be
largely mediated via eNOS and NO itself is an upstream pro-
moter of VEGF expression; Papapetropoulos et al., 1997a,b).
The decreased myocardial angiogenesis in eNOS deficient mice
could very well contribute to myocardial apoptosis, progressive
heart failure, and increased mortality by resulting in the forma-
tion of an insufficiently vascularized vascular bed, leading to
chronic ischemia. Furthermore, abnormal angiogenesis and
capillary development in various vascular beds could very
well be the root cause of the moderate systemic hypertension,
mild elevation in pulmonary vascular resistance, and the exag-
gerated pulmonary vasoconstrictor response to hypoxia noted
in the adult animals (Zhao et al., 2002).
In addition, in vivo studies have suggested a role for eNOS-
derived NO in the closure and remodeling of the ductus arter-
iosus, the fetal vascular shunt between the aorta and pulmonary
artery (Richard et al., 2004). Preterm administration of L-
NAME to pregnant female rats on E19 resulted in increased
ductal constriction in the fetuses (Takizawa et al., 2000).
NO in vitelline vasculogenesis
The importance and complexity of NO production and sig-
naling are manifested in the development of the vitelline vas-
culature. Establishment of the extra-embryonic vasculature is
crucial for survival, growth, and homeostasis in the vertebrate
embryo. The use of whole conceptus culture has been importantin facilitating our understanding of the roles of selected growth
factors (Pinter et al., 2001), cell adhesion molecules (Enciso et
al., 2003; Pinter et al., 1997, 1999, 2001), and enzymes (Nath et
al., 2004) during normal and hyperglycemia-induced dysregu-
lated vitelline circulation and endocardial cushion develop-
ment. Using this model (Figs. 1A–D), we have determined
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both the endodermal and mesodermal compartments of the yolk
sac during the stages of vasculogenesis through remodeling and
arborization of the vasculature (Figs. 1E–J) (Nath et al., 2004).
Namely, iNOS expression appears localized in the endodermal
compartment at E8.0 and is non-detectable at later time points,
while eNOS is initially present in the mesodermal compartment
in low amounts at E8.0, but its expression increases in the
differentiating endothelial cells at E8.5 and E9.5. In addition
to the changing localization patterns of iNOS and eNOS during
yolk sac vascular development, their protein levels were also
noted to change, with iNOS progressively decreasing from
E7.5 to E9.5, while eNOS was noted to progressively increase
during this time period (Figs. 1K and L). This inverse relation-
ship in iNOS and eNOS expression has been noted during
cardiac development albeit at a different time period of devel-
opment (E14.5) (Bloch et al., 1999), but it suggests a similar
dynamic NOS isoform relationship, perhaps being indicative of
a general switch in isoform expression during distinct differen-
tiation processes.
Interestingly, the early robust expression of iNOS in the
endodermal compartment is associated with robust endodermal
NO production in the conceptus (Nath et al., 2004). This is
followed temporally by an increased expression of VEGF at
E8.5 (Madri et al., 2003), consistent with the notion that NO is
an upstream promoter of VEGF expression (Jozkowicz et al.,
2001, 2004). This concept is supported by data accrued by Han
et al. in which they observed that mRNA levels of VEGF-A and
angiopoietin-1 were reduced in eNOS null mice and these mice
exhibited impaired pulmonary angiogenesis. Interestingly, this
pulmonary vascular pathology mimics a disease entity found in
the human newborn population, human alveolar capillary dys-
plasia (Han et al., 2004), again suggesting that dysregulation of
NO could be a cause of a human vascular disease. Additional
targets of NO during the development and differentiation of the
vitelline and other vasculatures are currently unknown and
warrant investigation.
Dysregulation of NO in the yolk sac by hyperglycemia: a model
explaining increased congenital abnormalities in the offspring
of diabetic mothers?
Offspring of diabetic mothers (both humans and experimen-
tal animals) experience a two- to four-fold increase in congen-
ital anomalies (Eriksson et al., 1991; Kitzmiller et al., 1996).
Although no particular organ system or tissue appears to be
specifically targeted, a variety of cardiovascular anomalies are
frequently observed and comprise one of the more common
birth defects (1% of live births) that carry a significant mortality
(21%) (Ferencz et al., 1990). In addition to the increased
incidence of congenital anomalies noted in the live births and
stillborns of diabetic mothers, these mothers experience diffi-
culties in becoming pregnant and exhibit an increased incidence
of fetal resorption (Baker and Piddlington, 1993; Ellington,
1997; Eriksson et al., 1991; Pampfer et al., 1997; Schwarz
and Teramo, 2000). Following implantation and before placen-
tation, embryonic growth is dependent upon proper develop-ment of the yolk sac vasculature and the vitelline circulation.
Arrested or mal-development of this vasculature would lead to
fetal demise at early gestation contributing to difficulty in
maintaining pregnancy, while arrest and/or mal-development
of vasculature(s) at later times, associated with specific organ/
tissue development, would contribute to congenital abnormali-
ties in a wide variety of organs/tissues.
It has previously been shown that in vitro cultures of rat and
mouse conceptuses at the primitive streak stage maintain via-
bility and the conceptuses develop near normally for 48 h,
during the initial stages of organogenesis. During this period,
they are nourished via the vitelline circulation (Pinter et al.,
1986, 1999) which initially develops prior to the onset of
organogenesis. The addition of 20 mM D-glucose (a plasma
concentration of glucose often observed in diabetic mothers
(both in humans and experimental animals) to these cultures
results in significant yolk sac and embryonic vasculopathy and
abnormal embryonic development (Pinter et al., 1999). Recent-
ly, we have demonstrated that VEGF expression is dysregulated
in these D-glucose-treated embryos and in the offspring of
streptozotocin-induced diabetic pregnant mice (Madri et al.,
2003; Pinter et al., 1999, 2001). In light of these findings and
data illustrating crucial roles of several growth factors and their
receptors during early vasculo- and angiogenesis (Tammela et
al., 2005), we investigated whether NOS isoform expression,
activities, and NO production was modulated in response to
hyperglycemic insult and whether hyperglycemia-induced yolk
sac vasculopathy could be rescued by addition of exogenous
NO donors.
Interestingly, we have noted that this glucose-induced vas-
culopathy is correlated with the persistence of iNOS expression
and a reduction in eNOS expression and could be reversed by
the addition of an exogenous NO donor, which correlated with
a correction of both iNOS and eNOS relative expression levels,
implicating NO as a crucial modulator of early vasculogenesis
(Madri et al., 2003; Nath et al., 2004; Pinter et al., 1999, 2001).
Additionally, exogenous addition of L-NMMA arrested yolk
sac vascular development at the primary capillary plexus
stage (not shown) as does hyperglycemic insult. The rescue of
the vitelline vasculo- and angiogenesis process by exogenous
NO donor suggests the possible future development and poten-
tial therapeutic use of NO donors in the treatment of maternal
diabetes-induced embryonic vasculopathy.
While dysregulation of NOS and NO has been implicated as
being intimately involved in the development of diabetic vas-
culopathy (Naseem, 2005), our understanding of the specific
mechanisms involved is still incompletely appreciated. One
area that has received considerable attention is the increased
production of ROS (reactive oxygen species) in hyperglycemia
(resulting in cellular toxicity), leading to a depletion of NO
(resulting in dysregulation of NO signaling) during embryonic
development (Brodsky et al., 2001; Mügge et al., 1991; Urbich
et al., 2002; Zhang et al., 2001). Indeed, conceptuses cultured
under hyperglycemic conditions exhibit increased ROS, while
similar cultures treated with an exogenous NO donor exhibit
normal vascular development and exhibit a partial decrease in
ROS expression, consistent with NO's antioxidant/scavenging
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al. demonstrated that iNOS knockout mice are less susceptible
to embryopathy by ROS-inducing agents during organogenesis,
a teratogen-sensitive stage (Kasapinovic et al., 2004).
An emerging area that may shed considerable light on the
underlying mechanism(s) at play in hyperglycemia-induced
embryonic vasculopathy is the potential dysregulation of pro-
tease activities by alteration of NO levels (Akool et al., 2005;
Chen and Wang, 2004; Phillips et al., 2001; Phillips and
Birnby, 2004). These investigators have demonstrated several
distinct NO-dependent pathways which, when NO levels are
altered, result in modulation of MMP-2, MMP-9, and TIMP-1,
with increased NO driving either: (1) decreased caveolin-1
levels which in turn are associated with decreased MMP-9
expression; (2) increased expression of the transcription factor
ATF-3, which in turn elicits a reduction in p53, leading to a
reduction in MMP-2 expression; and/or (3) increased TGF-β-
mediated Smad pathway induction of TIMP-1, which in turn
would inhibit MMP-9.
Thus, dysregulation of NO levels resulting in alteration of
either ROS-mediated cell motility/migration (Gratzinger et al.,
2003; Ushio-Fukai and Alexander, 2004) and/or MMP expres-
sion (Akool et al., 2005; Chen and Wang, 2004; Phillips et al.,
2001; Phillips and Birnby, 2004) would have profound effectsFig. 2. Potential mechanisms of hyperglycemia-induced NO-mediated arrest of vite
ROS levels may affect lamellipodia formation and motility/migration of endothelial
epithelial to mesenchymal transformation in endocardial cushions. (B) NO modulati
altering transcription via ATF-3 and p53), and/or activity (by altering TIMP-1 level
epithelial to mesenchymal transformation in endocardial cushions. (a, b, c and d
normoglycemic conditions (a and b) or hyperglycemic conditions (c and d), illustr
grown under normoglycemic conditions (5 mM D-glucose) (a and b) and an abnorm
consistent with a vasculature arrested at the primary capillary plexus stage in conceptu
based on data from Akool et al. (2005), Chen and Wang (2004), Phillips et al. (2001),
(2004), Pinter et al. (1997), Pinter et al. (1999), Pinter et al. (2001), Nath et al. (200on development of the vitelline circulation (Nath et al., 2004)
and endocardial cushion formation (Enciso et al., 2003) (Fig. 2).
Given the advances in gene targeting and delivery, small
molecule design and delivery and in optimizing strategies that
appropriately scavenge increased ROS and/or restore NO levels
and signaling during early embryonic development (organogen-
esis), NOS/NO-based therapies are becoming approachable and
with more investigation have the potential of developing into
beneficial therapeutic approaches for cardiovascular and other
diseases in the future (Channon et al., 2000; Chen et al., 2002).
Conclusions
As mentioned throughout this text, NOS isoforms and their
product, NO, are important (critical) modulators of develop-
mental processes, ranging from the preimplantation through the
perinatal period. In spite of intense investigation, many of the
process- and stage-specific targets of NO and their up- and
down-stream signaling cascades are incompletely elucidated.
With the elucidation of the mechanisms at play during specific
stages of development and during the development of particular
organs/tissues will come the possibility to intervene favorably
in several NO-mediated processes that are known or suspected
to be dysregulated in several disease states.lline circulation and endocardial cushion development. (A) NO modulation of
cells, arresting vascular remodeling of the yolk sac primary capillary plexus and
on of MMP cellular localization (by altering Cav-1 expression), expression (by
s) may affect vascular remodeling of the yolk sac primary capillary plexus and
) Representative micrographs of murine 9.5 dpc conceptuses cultured under
ating a well-developed arborizing, mature vitelline vasculature in conceptuses
al vitelline vasculature comprised of ecstatic vessels displaying no arborization,
ses grown under hyperglycemic conditions (20 mM D-glucose) (c and d). Figure
Phillips and Birnby (2004), Gratzinger et al. (2003), Ushio-Fukai and Alexander
4), and Enciso et al. (2003).
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